Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$44 Mln
P/E Ratio
--
P/B Ratio
32.03
Industry P/E
--
Debt to Equity
-1.86
ROE
-5.05 %
ROCE
-175.45 %
Div. Yield
0 %
Book Value
--
EPS
-0.56
CFO
$-576.62 Mln
EBITDA
$-789.01 Mln
Net Profit
$-797.11 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Mersana Therapeutics (MRSN)
| -73.71 | -11.61 | -31.62 | -88.43 | -54.22 | -46.39 | -- |
|
BSE Sensex*
| 2.39 | 4.18 | 4.86 | 8.78 | 11.89 | 20.62 | 11.13 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Mersana Therapeutics (MRSN)
| -38.12 | -60.41 | -5.79 | -76.63 | 364.40 | 40.44 | -74.98 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 36.48 | 9,808.03 | 20.22 | 23.13 | |
| 282.28 | 8,956.09 | 22.08 | 58.42 | |
| 25.74 | 9,559.25 | -- | -28.77 | |
| 101.74 | 10,030.35 | 30.81 | 14.16 |
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in... Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. Address: 840 Memorial Drive, Cambridge, MA, United States, 02139 Read more
President, CEO & Director
Dr. Martin H. Huber M.D.
President, CEO & Director
Dr. Martin H. Huber M.D.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Mersana Therapeutics Inc (MRSN) stood at $ 145 Mln as on 31-Dec-24
The share price of Mersana Therapeutics Inc (MRSN) is $0.38 (NASDAQ) as of 22-Apr-2025 16:00 EDT. Mersana Therapeutics Inc (MRSN) has given a return of -54.22% in the last 3 years.
Mersana Therapeutics Inc (MRSN) has a market capitalisation of $ 44 Mln as on 21-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Mersana Therapeutics Inc (MRSN) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Mersana Therapeutics Inc (MRSN) and enter the required number of quantities and click on buy to purchase the shares of Mersana Therapeutics Inc (MRSN).
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs. The company develops Emi-Le (XMT-1660), a B7-H4-targeting Dolasynthen ADC candidate, which is in Phase 1 clinical trial; and XMT-2056, an Immunosynthen ADC targeting a novel human epidermal growth factor receptor 2 that is in Phase 1 clinical trial. Its preclinical products portfolio includes XMT-2068 and XMT-2175. It has strategic research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana Biosciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts. Address: 840 Memorial Drive, Cambridge, MA, United States, 02139
The CEO & director of Dr. Martin H. Huber M.D.. is Mersana Therapeutics Inc (MRSN), and CFO & Sr. VP is Dr. Martin H. Huber M.D..
There is no promoter pledging in Mersana Therapeutics Inc (MRSN).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Mersana Therapeutics Inc. (MRSN) | Ratios |
|---|---|
|
Return on equity(%)
|
-505.14
|
|
Operating margin(%)
|
-160.26
|
|
Net Margin(%)
|
-170.86
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Mersana Therapeutics Inc (MRSN) was $0 Mln.
$0.05
(
